The drug-device interface.

I R Cutler

Home/Archive/PubMed

PubMed · 10171678

The drug-device interface.

I R Cutler

View original source ↗Export metadata ↓

Abstract

The difference between a drug and a device appears clear, but there are instances when the distinction between a product being a drug or a device is blurred. By making reference to the EC Directives for medicinal products and medical devices, this article seeks to clarify the definition of a medical device that incorporates or administers a drug.

Explore related subjects

Drug Delivery Systems Equipment Safety European Union Humans Legislation, Drug Legislation, Medical Pharmaceutical Preparations Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

I R Cutler. 1993. The drug-device interface.. https://pubmed.ncbi.nlm.nih.gov/10171678/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.

The synthesis and abl tyrosine kinase inhibitory activities of alkyltriazenes conjugated to phenylaminopyrimidines are described. Significant abl inhibitory activities were observed only when a benzamido spacer was inserted between the 1,2,3-triazene chain and the 2-phenyaminopyridopyrimidine moiety.

Drug Delivery Systems↗

PubMed2003

NMR-based screening technologies.

NMR-based ligand screening is now an established field in its own right. In recent years, advances in both methodology and hardware have broadened its range of applications and pushed back practical limitations, leading to the growing importance of NMR screening as a tool in industrial drug research. An overview of new screening methods and applications is presented here, and ways in which NMR-screening is being used in cooperation with other screening techniques are discussed.

Drug Delivery Systems↗

PubMed2003

G protein-coupled receptor microarrays for drug discovery.

The dominance of G protein-coupled receptors (GPCRs) as a drug target class, coupled with the increased pace of target identification and expansion of compound libraries, presents a compelling need to develop technologies to screen multiple GPCRs simultaneously. To address this need, GPCR microarrays that require the co-immobilization of lipid molecules and the probe receptors of interest have been fabricated, using conventional robotic printing technologies. Assays to screen compounds for their pharmacological properties (binding affinity, relative potency and selectivity) using GPCR microarrays are discussed.

Drug Delivery Systems↗